Recommendations

ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
Guideline
Table 30. Continued
Deaths MI, Restenosis, TLR,
Active/Control, Active/Control, Active/Control, Active/Control,
% % % %
Eluting n, Eluting Drug
Drug Trial (Ref.) Year Active/Control Stent Dosage
NA NA 13.3 at 6 months 20 at 6 months
61.5 at 1 year 60 at 1 year
Paclitaxel QuaDS- 2002 15 QuaDS- 2400 to 3200 mcg
QP2 (884) QP2 total dose
0.9/0 2.6/1.7 4/12/27 at 4 to 6 2/2/2 at 1 to
months (high dose 6 months
vs control,
P less than 0.001)
ASPECT (885) 2003 59 High dose Supra-G 3.1 mcg/mm 2
58 low dose/ 1.3 mcg/mm 2
59 control
0/0 0/0 0/10 at 6 months 0/10 at 1 year
(P equals 0.012) (P equals 0.237)
TAXUS I (886) 2003 31/30 NIR 1.0 mcg/mm 2
0/0.8 3.1/5.3 7.1/21.9 at 6 months 10.4/21.7
at 12 months
TAXUS II (887) 2003 266/279 NIR 1.0 mcg/mm 2
NA NA NA 21.4 at 1 year
TAXUS III (888) 2003 28 ISR NIR 1.0 mcg/mm 2
1.4/1.1 3.5/3.7 7.9/26.6 at 9 months 4.4/15.1 at 1 year
(P less than 0.0001) (P less than 0.0001)
TAXUS IV (697) 2004 662/652 EXPRESS 1.0 mcg/mm 2
ACS indicates cute coronary syndromes; ASPECT, Asian Paclitaxel-Eluting Stent Clinical Trial; FIM, First in Man; ISR, in-stent restenosis; NA, not applicable; RESEARCH, Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital; SIRIUS,
Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (C-SIRIUS indicates Canadian study; E-SIRIUS, European study); and TLR, target-lesion revascularization.
Smith et al. 2005
ACC/AHA/SCAI
83